Plasma lipoproteins, antihypertensive drugs and coronary heart disease

Area of Science:

• Cardiology
• Pharmacology
• Metabolic Diseases

Background:

• Coronary atherosclerosis susceptibility is linked to plasma lipid levels and blood pressure.
• High-density lipoprotein (HDL) cholesterol is inversely related, while low-density lipoprotein (LDL) and blood pressure are directly related to risk.
• Evidence suggests causal roles for HDL and LDL in atherogenesis and protection.

Purpose of the Study:

• Investigate the impact of antihypertensive drugs on plasma lipoprotein profiles.
• Explore reasons for the failure of some antihypertensive drugs to reduce coronary heart disease incidence in clinical trials.
• Understand the potential mechanisms linking blood pressure management and cardiovascular outcomes.

Main Methods:

• Review of existing evidence on drug effects on coronary disease and experimental atherosclerosis.
• Analysis of clinical trial data concerning antihypertensive therapies and coronary heart disease incidence.
• Examination of the effects of beta-blockers and thiazides on plasma lipoprotein ratios (HDL/LDL).

Main Results:

• Several beta-blocking drugs and thiazides demonstrate a theoretically adverse effect on the HDL to LDL cholesterol ratio.
• Antihypertensive drugs have shown efficacy in reducing other complications of high blood pressure.
• The reduction in coronary heart disease incidence has not been consistently observed in trials using these drugs.

Conclusions:

• Adverse changes in lipoprotein metabolism induced by certain antihypertensive medications may offset the protective effects of blood pressure reduction.
• The precise mechanisms and clinical consequences of these lipoprotein alterations require further investigation.
• Understanding these effects is crucial for optimizing cardiovascular risk management in hypertensive patients.